Cytovance Biologics has been awarded a manufacturing contract to continue development of BiologicMD’s osteoporosis drug, PTH-CBD. The agreement will lead to the development of the manufacturing platform that will allow BiologicsMD to conduct Phase I studies.
“We are excited to announce our partnership with Cytovance to develop the manufacturing platform for our PTH-CBD treatment. Their expertise will play a key role in accelerating the development of this compound that will hopefully improve the lives of the millions of individuals who suffer from osteoporosis,” said Paul Mlakar, Jr., president of BiologicsMD.
“Cytovance is excited that BiologicsMD has chosen us to support this innovative treatment for osteoporosis,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our experienced staff and state-of-the-art facilities are prepared to deliver the highest quality of manufacturing services for successful completion of this clinical milestone for the PTH-CBD program.”